Sanderson F, Poullin P, Smith R, Nicolino-Brunet C, Philip P, Chaib A, Costello R
CHU La Conception, Service d'hémaphérèse Auto Transfusion.
Terumo BCT, Lakewood, Colorado, USA.
J Clin Apher. 2017 Jun;32(3):182-190. doi: 10.1002/jca.21485. Epub 2016 Jul 21.
The aim of the study was to assess the performance of the new Continuous Mononuclear Cell Collection (CMNC) protocol on the Spectra Optia Apheresis System for collecting autologous Peripheral Blood Stem Cells (PBSC) in adult patients with respect to collection variables, CD34+ cells harvest prediction and engraftment data. In this retrospective study, 39 CMNC procedures on 23 mobilized patients with multiple myeloma and lymphoma were analyzed. CD34+ cells and blood cells yields, collection efficiencies (CE1 and CE2), cell losses were calculated. Engraftment data of 17 autologous transplantations were collected.
Apheresis duration was 239 min for a product volume of 220 mL. Cell product haematocrit, MNC and platelets counts were acceptable (respectively 2.4%, 65%, 834 x 109/L). Median platelet loss was 27.3%. Median CD34+ CE1 and CE2 were 64.6% and 48.5% respectively. We harvested 2.92 × 10 CD34+ cells/kg, with a CD34 dose ≥ 2 × 10 /kg for 67% of the procedures. Linear correlation between preapheresis CD34 count and the CP CD34 dose/kg allowed a prediction model with a decrease trend for high WBC precount. Procedures were well tolerated. For 17 autologous transplantations, median time to neutrophils and platelets reconstitutions were 12 and 13 days respectively.
Spectra Optia CMNC protocol successfully collected CD34+ cells with yields permitting the harvest of sufficient enriched grafts for autologous transplantation. The CD34+ cell yield prediction was excellent. PBSC collection with CMNC protocol had advantages of high processing rate, low product volume, and acceptable contamination by platelets. J. Clin. Apheresis 32:182-190, 2017. © 2016 Wiley Periodicals, Inc.
本研究旨在评估新的连续单核细胞采集（CMNC）方案在Spectra Optia血液成分分离系统上采集成年多发性骨髓瘤和淋巴瘤患者自体外周血干细胞（PBSC）时，在采集变量、CD34+细胞收获预测和植入数据方面的表现。在这项回顾性研究中，分析了23例动员的多发性骨髓瘤和淋巴瘤患者的39次CMNC程序。计算了CD34+细胞和血细胞产量、采集效率（CE1和CE2）以及细胞损失。收集了17例自体移植的植入数据。
血液成分分离持续时间为239分钟，产品体积为220毫升。细胞产品血细胞比容、单核细胞（MNC）和血小板计数均可接受（分别为2.4%、65%、834×10⁹/L）。血小板损失中位数为27.3%。CD34+ CE1和CE2中位数分别为64.6%和48.5%。我们采集到2.92×10⁶个CD34+细胞/千克，67%的程序CD34剂量≥2×10⁶/千克。采集前CD34计数与采集产品CD34剂量/千克之间的线性相关性使得能够建立一个针对高白细胞预计数呈下降趋势的预测模型。程序耐受性良好。对于17例自体移植，中性粒细胞和血小板重建的中位时间分别为12天和13天。
Spectra Optia CMNC方案成功采集到CD34+细胞，其产量足以收获用于自体移植的充足富集移植物。CD34+细胞产量预测良好。采用CMNC方案进行PBSC采集具有处理速度快、产品体积小以及血小板污染可接受等优点。《临床血液成分分离杂志》32:182 - 190，2017年。©2016威利期刊公司。
